OBJECTIVE: The purpose of the study was to examine whether miR-887-5p could be used as a diagnostic marker for endometrial cancer. METHODS: In the first stage, differentially expressed serum micro-RNAs (miRNAs) in the sera of 50 healthy subjects and 50 patients with endometrial cancer were screened by performing Solexa sequencing. In addition, differential expression of these serum miRNAs in endometrial cancer tissues and adjacent normal tissues from 3 patients with endometrial cancer was examined. Comparison of the differentially expressed miRNAs showed that miR-887-5p was significantly expressed in the sera of patients with endometrial cancer as well as in endometrial cancer tissues. In the second stage, quantitative reverse transcription polymerase chain reaction was performed to verify the levels of miR-887-5p in the sera of 20 patients with endometrial cancer and of 20 healthy subjects. RESULTS: Expression of miR-887-5p was significantly increased in the sera of patients with endometrial cancer (P < 0.05) compared with that in the sera of healthy subjects. Receiver operating characteristic curve analysis showed that the area of miR-887-5 under the ROC curve for endometrial cancer diagnosis was 0.728, specificity was 0.60, sensitivity was 0.95, and 95% confidence interval was 0.563-0.892. Besides, with strict screen, we eliminate the other risk factors of endometrial cancer in our healthy donors and cancer patients. Statistical analysis of data obtained for patients in the 2 stages by using SPSS version 17.0 indicated that menarche age (P = 0.47, P = 0.49), body mass index (P = 0.313, P = 0.749), history of hypertension (P = 0.517, P = 0.058), and diabetes (P = 0.205, P = 0.507) had no correlation with endometrial cancer. CONCLUSION: Serum miR-887-5p levels were significantly increased in patients with endometrial cancer. Therefore, serum miR-887-5p could be used as a potential biomarker for endometrial cancer.
OBJECTIVE: The purpose of the study was to examine whether miR-887-5p could be used as a diagnostic marker for endometrial cancer. METHODS: In the first stage, differentially expressed serum micro-RNAs (miRNAs) in the sera of 50 healthy subjects and 50 patients with endometrial cancer were screened by performing Solexa sequencing. In addition, differential expression of these serum miRNAs in endometrial cancer tissues and adjacent normal tissues from 3 patients with endometrial cancer was examined. Comparison of the differentially expressed miRNAs showed that miR-887-5p was significantly expressed in the sera of patients with endometrial cancer as well as in endometrial cancer tissues. In the second stage, quantitative reverse transcription polymerase chain reaction was performed to verify the levels of miR-887-5p in the sera of 20 patients with endometrial cancer and of 20 healthy subjects. RESULTS: Expression of miR-887-5p was significantly increased in the sera of patients with endometrial cancer (P < 0.05) compared with that in the sera of healthy subjects. Receiver operating characteristic curve analysis showed that the area of miR-887-5 under the ROC curve for endometrial cancer diagnosis was 0.728, specificity was 0.60, sensitivity was 0.95, and 95% confidence interval was 0.563-0.892. Besides, with strict screen, we eliminate the other risk factors of endometrial cancer in our healthy donors and cancerpatients. Statistical analysis of data obtained for patients in the 2 stages by using SPSS version 17.0 indicated that menarche age (P = 0.47, P = 0.49), body mass index (P = 0.313, P = 0.749), history of hypertension (P = 0.517, P = 0.058), and diabetes (P = 0.205, P = 0.507) had no correlation with endometrial cancer. CONCLUSION: Serum miR-887-5p levels were significantly increased in patients with endometrial cancer. Therefore, serum miR-887-5p could be used as a potential biomarker for endometrial cancer.